Peptide vaccines designed from the cancer-associated protein CD151 activated killer T cells and suppressed immune-blocking cells, fighting both primary liver tumors and breast cancer lung metastases in mice.
Prolonged survival in lung metastasis modelCD151 peptide vaccination activated CD8+IFNγ+ T cells and suppressed MDSCs, providing dual anti-tumor mechanisms in both primary and metastatic cancer models
What the researchers found
Peptides derived from the oncoprotein CD151 triggered active anti-tumor immunity in two mouse cancer models — H22 hepatoma (primary liver cancer) and 4T1 breast cancer lung metastases. The peptide vaccines activated CD8+IFNγ+ killer T cells and suppressed myeloid-derived suppressor cells (MDSCs), a key immunosuppressive population in tumors. Mice immunized with CD151 peptides showed prolonged survival in the lung metastasis model. CD151 was identified as an ideal tumor-associated antigen through proteomic analysis of radiation-stressed tumor cells.
Why it matters
Unlike personalized neoantigen vaccines that must be custom-designed for each patient, CD151 is an oncoprotein that is broadly overexpressed across many cancer types — making it a potential off-the-shelf vaccine target. The approach of identifying antigens that become upregulated under radiation stress could reveal other promising targets. The dual mechanism — activating killer T cells while suppressing immunosuppressive cells — addresses two major hurdles in cancer immunotherapy.
The numbers in context
2 mouse cancer models (H22 hepatoma, 4T1 breast metastasis) · CD8+IFNγ+ T cell activation · MDSC suppression · Prolonged survival in metastasis model · 8 Gy irradiation for antigen discovery
How the study worked
Proteomic and bioinformatic analyses of 8 Gy-irradiated tumor cells identified CD151 as a tumor-associated antigen. Peptides were designed based on MHC-I binding predictions and immunogenicity analysis, then synthesized. Efficacy was tested in H22 hepatoma and 4T1 breast cancer lung metastasis mouse models using cytotoxicity assays, flow cytometry, immunohistochemistry, in vivo bioluminescence imaging, and survival analysis.
Who was studied
Preclinical study using H22 hepatoma and 4T1 breast cancer lung metastasis mouse models
What this study cannot tell us
This is a preclinical mouse study using two tumor models. Human CD151 expression patterns and immunogenicity may differ. The long-term durability of the immune response was not characterized. Whether CD151 peptide vaccines would be effective against established, bulky tumors (rather than early-stage or metastatic seeding) is unclear. Safety regarding potential autoimmunity against normal CD151-expressing tissues was not deeply explored.
How to read the evidence
This is a preclinical animal study demonstrating proof of concept in two mouse tumor models. While the results are promising — particularly the dual mechanism and survival benefit — human clinical trials would be needed to assess safety and efficacy.
When this study was published
Published in 2019, this study represents an ongoing area of research in peptide-based cancer vaccines targeting shared tumor antigens. The approach complements the personalized neoantigen vaccine strategies being pursued by other groups.
The bigger picture
Cancer vaccines have had a mixed track record, but the field is experiencing a renaissance with advances in neoantigen prediction, mRNA delivery, and combination immunotherapy. CD151 peptide vaccines represent a shared-antigen approach — potentially simpler and cheaper than personalized vaccines since CD151 is overexpressed in many cancer types. The strategy of identifying vaccine targets from radiation-stressed tumors is also novel and could yield additional candidates. The suppression of MDSCs is particularly significant, as these cells are a major barrier to immunotherapy success.
Questions still open
- Would CD151 peptide vaccines be effective in human cancers, and which cancer types would be most responsive based on CD151 expression levels?
- Could combining CD151 peptide vaccination with checkpoint inhibitors or radiation therapy further enhance the anti-tumor response?
- Is there a risk of autoimmune reactions against normal tissues that express CD151, such as platelets and endothelial cells?
Common questions
What is CD151 and why is it a good cancer vaccine target?
How is this different from other cancer vaccines?
Read the original research
Peptides of tetraspanin oncoprotein CD151 trigger active immunity against primary tumour and experimental lung metastasis.
EBioMedicine, 49, 133-144
Citation
Lin, Wanzun; Liu, Jun; Chen, Juhui; Li, Jiancheng; Qiu, Sufang; Ma, Jiayu; Lin, Xiandong; Zhang, Lurong; Wu, Junxin. (2019). Peptides of tetraspanin oncoprotein CD151 trigger active immunity against primary tumour and experimental lung metastasis.. EBioMedicine, 49, 133-144. https://doi.org/10.1016/j.ebiom.2019.10.025